ENERGY Study

ENERGY Study

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is no longer recruiting.

Description

TheENERGY study is for adults (ages 18 and up) with warm Autoimmune HemolyticAnemia (wAIHA) who are currently receiving treatment or have previously receivedtreatment. Thegoal of the study is to see if the study drug, Nipocalimab is safe andeffective in the treatment of wAIHA. Nipocalimab is an investigationalmedication designed to stop your immune system from destroying your red blood cells.

You may be able to join the study if you are: 
  •          18 years of age or older.
  •          Diagnosed with wAIHA for at least 3months.
  •          Currently receiving treatment orhave previously received treatment for wAIHA
  •          Have platelet counts of more than30,000/ L and Hemoglobin less than 10 g/dL

 Other studyrequirements will apply.

Eligibility and criteria
IRB Number:
19-016799
Eligible age range:
18 years - 100 years
Clinical trial phase:
Phase II
Phase III
Official title:
Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study with a Long-term Open-label Extension

What to expect

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.